Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib

To the Editor: Crizotinib has been shown to have therapeutic activity in relapsed and resistant ALK-positive lymphomas. Some patients receive treatment for more than 4 years without recurrence. We describe two cases of abrupt relapse in patients with ALK-positive anaplastic large-cell lymphoma…

from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/1RusJbp
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1JZazrX
via IFTTT